Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations
Open accessThe DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
Previous guidelines for the treatment of people with type 2 diabetes mellitus (T2D) have relied heavily upon rigid algorithms for the sequential addition of pharmacotherapies to achieve target glycemic control. More recent guidelines advocate a personalized approach for diabetes treatment, to improve patient satisfaction, quality of life, medication adherence and overall health outcomes. Clinicians should work with patients to develop personalized goals for their treatment, including targeted glycemic control, weight management, prevention and treatment of associated comorbidities and avoidance of complications such as hypoglycemia. Factors that affect the intensity of treatment and choice of pharmacotherapy should include medical and patient influences. Medical considerations include the diabetes phenotype, biomarkers including genetic tests, and the presence of comorbidities such as cardiovascular, renal, or hepatic disease. Patient factors include their treatment preference, age and life expectancy, diabetes duration, hypoglycemia fear and unawareness, psychological and social circumstances. The use of a personalized approach in the management of people with T2D can reduce the cost and failure associated with the algorithmic "one-size-fits-all" approach, to anticipate disease progression, improve the response to diabetes pharmacotherapy and reduce the incidence of diabetes-associated complications. Ultimately, the use of personalized medicine in people with T2D should improve medication adherence, patient satisfaction and quality of life to reduce diabetes distress and improve physical health outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 2×
“Their use in people with T2D can support an additional weight loss of 2 to 4kg.76 Metformin use is considered at least weight neutral though may be associated with a modest weight loss, as observed in the Diabetes Prevention Program.81 The use of DPP-IV inhibitors in people with T2D is considered weight neutral.82 The…”
BackgroundEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“9kg in people with T2D.(51) In a dedicated weight loss trial of overweight and obese patients (with or without T2D), semaglutide 2.”
BackgroundDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“9% body weight).(78) In the REWIND study, dulaglutide was associated with 1.”
BackgroundEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 2×
“In patients with older age or reduced life expectancy, a personalized glycemic target acceptable to the patient and clinician to minimize the risk of harm should be agreed.(31) Consensus guidelines advocate less aggressive glycemic targets in people with T2D in this patient group.”
BackgroundSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Self-citationA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Ahlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus
Kautzky-Willer, A., Harreiter, J., & Pacini, G. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1137 · Cited by 2,043
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 1×
“4mg subcutaneous semaglutide daily.(71) Similarly, use of dulaglutide 1.”
BackgroundOral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Mahajan, A., Taliun, D., Thurner, M., Robertson, N. R., Torres, J. M., Rayner, N. W., Payne, A. J., Steinthorsdottir, V., Scott, R. A., Grarup, N., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0241-6 · Cited by 1,744 · cited 1×
“Indeed, recent progress in this area of genomics utilizing genome-wide association studies (GWAS) has identified more than 400 genetic variants associated with the development of T2D, each with a small effect on the net phenotype.(101,102) These genetic factors are mostly common genetic variants, and the relative sign…”
BackgroundBasal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Cardiovascular outcomes with ertugliflozin in type 2 diabetes
Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004967 · Cited by 1,514
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s006 · Cited by 847
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 1×
“Interestingly, tirzepatide, a combination GLP-1RA and glucose-dependent insulinotropic peptide (GIP) agonist has been observed to have major impact to improve glycaemic control and support weight loss, greater than that observed with other GLP-1RA or basal insulin.(79,80) However, this combination drug is not yet appr…”
ResultPolonsky, W., & Henry, R. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s106821 · Cited by 784 · cited 2×
“Patient factors may include lower educational attainment, lower income, perceptions around treatment efficacy and the actual impact of T2D on their health.(28) Clearly, these factors ought to be considered when approaching a holistic management strategy in T2D patients.”
BackgroundA practical review of C-peptide testing in diabetes
Leighton, E., Sainsbury, C. A., & Jones, G. C. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0265-4 · Cited by 773 · cited 2×
“Indeed, the presence (or absence) of these biomarkers associates with the response to non-insulin- and insulin-based therapies for T2D, and often guides personalized treatment choices already in current clinical practice.(105,106)”
BackgroundLudvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639 · cited 1×
“Interestingly, tirzepatide, a combination GLP-1RA and glucose-dependent insulinotropic peptide (GIP) agonist has been observed to have major impact to improve glycaemic control and support weight loss, greater than that observed with other GLP-1RA or basal insulin.(79,80) However, this combination drug is not yet appr…”
ResultRosenstock, J., Kahn, S. E., Johansen, O. E., Zinman, B., Espeland, M. A., Woerle, H. J., Pfarr, E., Keller, A., Mattheus, M., Baanstra, D., et al. (2019) · JAMA · doi:10.1001/jama.2019.13772 · Cited by 612
Efficacy and safety of degludec versus glargine in type 2 diabetes.
Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615692 · Cited by 574
The mental health comorbidities of diabetes
Ducat, L., Philipson, L. H., & Anderson, B. J. (2014) · JAMA · doi:10.1001/jama.2014.8040 · Cited by 402
Complications in Young Adults With Early-Onset Type 2 Diabetes
Hillier, T. A., & Pedula, K. L. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.2999 · Cited by 389
Clinical Use of DPP-4 Inhibitors
Gallwitz, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00389 · Cited by 374
Colosia, A., Khan, S., & Palencia, R. (2013) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s51325 · Cited by 369
Daousi, C., Casson, I. F., Gill, G. V., MacFarlane, I. A., Wilding, J. P. H., & Pinkney, J. H. (2006) · Postgraduate Medical Journal · doi:10.1136/pmj.2005.039032 · Cited by 351 · cited 1×
“In people with T2D, the prevalence of obesity is greater, with some studies estimating the prevalence of patients with obesity at around 50% and 35% are overweight.(73) Obesity is associated with greater all-cause mortality and was associated with over 4 million deaths worldwide in 2015, largely a result of excess car…”
BackgroundBeta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., & DeFronzo, R. A. (2004) · Diabetologia · doi:10.1007/s00125-003-1263-9 · Cited by 338
Han, Y., Xie, H., Liu, Y., Gao, P., Yang, X., & Shen, Z. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0900-7 · Cited by 337 · cited 1×
“One meta-analysis reported that metformin reduced the rate of cardiovascular events, cardiovascular mortality and all-cause mortality.(53) Compared with other treatments, sulphonylurea use in people with T2D was associated with increased cardiovascular and all-cause mortality.”
Kerr, E. A., Heisler, M., Krein, S. L., Kabeto, M., Langa, K. M., Weir, D., & Piette, J. D. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-007-0313-2 · Cited by 330
Schwartz, S. S., Epstein, S., Corkey, B. E., Grant, S. F. A., Gavin, J. R., & Aguilar, R. B. (2016) · Diabetes Care · doi:10.2337/dc15-1585 · Cited by 329
Solomon, S. D., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Lindholm, D., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2249 · Cited by 326
Precision diabetes: learning from monogenic diabetes
Hattersley, A. T., & Patel, K. A. (2017) · Diabetologia · doi:10.1007/s00125-017-4226-2 · Cited by 306
Genetic Risk Scores for Diabetes Diagnosis and Precision Medicine
Udler, M. S., McCarthy, M. I., Florez, J. C., & Mahajan, A. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00088 · Cited by 302
Kuchay, M. S., Krishan, S., Mishra, S. K., Choudhary, N. S., Singh, M. K., Wasir, J. S., Kaur, P., Gill, H. K., Bano, T., Farooqui, K. J., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05265-7 · Cited by 249 · cited 1×
“5mg weekly in patients with T2D and NAFLD significantly improved liver fat content and liver enzymes.(72) Unfortunately, there are no longer-term trials to evaluate the impact of SGLT2i or GLP-1RAs on major adverse hepatic outcomes such as cirrhosis, decompensated liver disease or hepatocellular carcinoma and longer f…”
BackgroundBody Weight Considerations in the Management of Type 2 Diabetes
Apovian, C. M., Okemah, J., & O’Neil, P. M. (2019) · Advances in Therapy · doi:10.1007/s12325-018-0824-8 · Cited by 239
Subtypes of Type 2 Diabetes Determined From Clinical Parameters
Ahlqvist, E., Prasad, R. B., & Groop, L. (2020) · Diabetes · doi:10.2337/dbi20-0001 · Cited by 229
Biomarkers for type 2 diabetes
Laakso, M. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.06.016 · Cited by 225
Mechanisms of hypoglycemia unawareness and implications in diabetic patients
Martín-Timón, I. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i7.912 · Cited by 204
Liao, H.-W., Saver, J. L., Wu, Y.-L., Chen, T.-H., Lee, M., & Ovbiagele, B. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013927 · Cited by 198
Drug therapy in obesity: a review of current and emerging treatments
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00816-y · Cited by 195 · cited 3×
“The pharmacological options for the treatment of obesity are growing, and GLP-1RAs are one of the modern main players.(76) These support weight loss by inducing satiety via hypothalamic stimulation and delayed gastric emptying.”
BackgroundResultInfluentialSelf-citationDiabetes and Aging: From Treatment Goals to Pharmacologic Therapy
Longo, M., Bellastella, G., Maiorino, M. I., Meier, J. J., Esposito, K., & Giugliano, D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00045 · Cited by 192
The role of bariatric surgery to treat diabetes: current challenges and perspectives
Koliaki, C., Liatis, S., le Roux, C. W., & Kokkinos, A. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0202-6 · Cited by 167
Schopman, J. E., Geddes, J., & Frier, B. M. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.013 · Cited by 150
Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis
Lian, J., & Fu, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.615409 · Cited by 136
Wong, J., Molyneaux, L., Constantino, M., Twigg, S. M., & Yue, D. K. (2008) · Diabetes Care · doi:10.2337/dc08-0580 · Cited by 132
Bain, S., Druyts, E., Balijepalli, C., Baxter, C. A., Currie, C. J., Das, R., Donnelly, R., Khunti, K., Langerman, H., Leigh, P., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12821 · Cited by 132
Georgianos, P. I., & Agarwal, R. (2019) · Diabetes Care · doi:10.2337/dc18-2207 · Cited by 130 · cited 1×
“6mmHg.(87) While pioglitazone use is associated with a reduced SBP of 3mmHg in trials,(88) its use is limited by the associated heart failure risk.”
BackgroundBeta- and Alpha-Cell Dysfunction in Type 2 Diabetes
Prato, S. D., & Marchetti, P. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826163 · Cited by 128
Sex and gender differences in therapy of type 2 diabetes
Kautzky‐Willer, A., & Harreiter, J. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.07.012 · Cited by 117
Riddle, M. C., Philipson, L. H., Rich, S. S., Carlsson, A., Franks, P. W., Greeley, S. A. W., Nolan, J. J., Pearson, E. R., Zeitler, P. S., & Hattersley, A. T. (2020) · Diabetes Care · doi:10.2337/dci20-0065 · Cited by 117
Chunxing, L., Liang, S., Gao, L., & Liu, H. (2021) · PLoS ONE · doi:10.1371/journal.pone.0244689 · Cited by 86
Carmody, D., Naylor, R. N., Bell, C. D., Berry, S., Montgomery, J. T., Tadie, E. C., Hwang, J. L., Greeley, S. A. W., & Philipson, L. H. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0859-8 · Cited by 84 · cited 1×
“Maturity-onset diabetes of the young (MODY) typically occurs in families with several generations in which diabetes develops as young adults with an autosomal dominant inheritance pattern and is frequently misdiagnosed as T2D.(99,100) With respect to MODY, multiple genes have been implicated in its development includi…”
BackgroundThe Genetic Epidemiology of Type 2 Diabetes: Opportunities for Health Translation
Meigs, J. B. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1173-y · Cited by 82 · cited 1×
“Indeed, recent progress in this area of genomics utilizing genome-wide association studies (GWAS) has identified more than 400 genetic variants associated with the development of T2D, each with a small effect on the net phenotype.(101,102) These genetic factors are mostly common genetic variants, and the relative sign…”
BackgroundPharmacogenomics in diabetes mellitus: insights into drug action and drug discovery
Zhou, K., Pedersen, H., Dawed, A. Y., & Pearson, E. R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.51 · Cited by 78
Clinical management of type 2 diabetes in south Asia
Misra, A., Sattar, N., Tandon, N., Shrivastava, U., Vikram, N. K., Khunti, K., & Hills, A. P. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30199-2 · Cited by 78
Precision Treatment and Precision Prevention: Integrating “Below and Above the Skin”
Gillman, M. W., & Hammond, R. A. (2016) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2015.2786 · Cited by 76
Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment
Kruger, D., LaRue, S., & Estepa, P. (2015) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s71923 · Cited by 73
Arambewela, M. H., Somasundaram, N. P., Ranjan Jayasekara, H. B. P., Kumbukage, M. P., Jayasena, P. M. S., Hemanthi Chandrasekara, C. M. P., Sudath Fernando, K. R. A., & Kusumsiri, D. P. (2018) · Journal of Diabetes Research · doi:10.1155/2018/4504287 · Cited by 70
Hayashino, Y., Izumi, K., Okamura, S., Nishimura, R., Origasa, H., Tajima, N., & the JDCP study group (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12550 · Cited by 66
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00747-3 · Cited by 64
Self-citationZhang, X., & Zhao, Q. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000782 · Cited by 62
The key role of islet dysfunction in type II diabetes mellitus.
Porte, D., & Kahn, S. E. (1995) · PubMed · Cited by 59
Bailey, C. J., & Day, C. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2004.00318.x · Cited by 52
Sheleme, T., Mamo, G., Melaku, T., & Sahilu, T. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s281992 · Cited by 52
Wang, J., Geiss, L. S., Cheng, Y. J., Imperatore, G., Saydah, S. H., James, C., & Gregg, E. W. (2011) · Diabetes Care · doi:10.2337/dc11-0178 · Cited by 51
Management of type 2 diabetes in chronic kidney disease
Triozzi, J. L., Gregg, L. P., Virani, S. S., & Navaneethan, S. D. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002300 · Cited by 51
van Dieren, S., Czernichow, S., Chalmers, J., Kengne, A. P., de Galan, B. E., Poulter, N., Woodward, M., Beulens, J. W. J., Grobbee, D. E., van der Schouw, Y. T., et al. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01556.x · Cited by 50
The Asian diabetes phenotypes: Challenges and opportunities
Chan, J. C. N., Yeung, R. O., & Luk, A. O. Y. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.05.011 · Cited by 45
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
Yin, W. L., Bain, S. C., & Min, T. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00798-x · Cited by 45
The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients
Snorgaard, O., Køber, L., & Carlsen, J. (1997) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1997.00236.x · Cited by 44
Hoerger, T. J., Zhang, P., Segel, J. E., Gregg, E. W., Narayan, K. M. V., & Hicks, K. A. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.09.017 · Cited by 41
Li, J. H., Szczerbiński, Ł., Dawed, A. Y., Kaur, V., Todd, J. N., Pearson, E. R., & Florez, J. C. (2020) · Diabetes · doi:10.2337/db20-0530 · Cited by 40
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14500 · Cited by 38
Williams, D. M., Nawaz, A., & Evans, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00951-6 · Cited by 37
Self-citationLim, L., Tan, A. T. B., Moses, K., Rajadhyaksha, V., & Chan, S. P. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.10.008 · Cited by 35
Williams, R., de Vries, F., Kothny, W., Șerban, C. I., López‐León, S., Chu, C., & Schlienger, R. G. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12951 · Cited by 31
Shrivastava, U., & Misra, A. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0213 · Cited by 27
Initiation of sulfonylureas versus metformin is associated with higher blood pressure at one year
Roumie, C. L., Liu, X., Choma, N. N., Greevy, R. A., Hung, A. M., Grijalva, C. G., & Griffin, M. R. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3249 · Cited by 23
Vincent, R. K., Williams, D. M., & Evans, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14196 · Cited by 22
Self-citationBhailis, A. M. D., Azmi, S., & Kalra, P. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211020664 · Cited by 21
Personalised treatment targets in type 2 diabetes patients: The Dutch approach
Boels, A. M., Hart, H. E., Rutten, G. E., & Vos, R. C. (2017) · Primary Care Diabetes · doi:10.1016/j.pcd.2016.08.001 · Cited by 20
Personalized medicine in Type 2 diabetes: what does the future hold?
Grant, R. W., & Wexler, D. J. (2012) · Diabetes Management · doi:10.2217/dmt.12.15 · Cited by 18
Karagiannis, T., Avgerinos, I., Toumpalidou, M., Liakos, A., Kitsios, K., Dimitriadis, G., Παπάνας, Ν., Bargiota, Α., Avramidis, I., Katsoula, A., et al. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05608-0 · Cited by 16
Pinto, L. C. F., Rados, D. R. V., Remonti, L. R., Viana, L. V., Pulz, G. T. C., Carpena, M. P., Borges, R. P., Marobin, R., Beretta, M. V., Pedrollo, E. F., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa534 · Cited by 14
Sujesh Kumar, N., & Subhakumari, K. N. (2015) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-015-0451-8 · Cited by 12
Cardiovascular safety of insulin: Between real‐world data and reality
Mannucci, E., & Ferrannini, E. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12967 · Cited by 9
Cited by
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s002 · Cited by 2,086
2. Diagnosis and classification of diabetes: standards of care in diabetes-2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Ebekozien, O., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s002 · Cited by 1,393
Piragine, E., Petri, D., Martelli, A., Calderone, V., & Lucenteforte, E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051981 · Cited by 149
Genetics of Type 2 Diabetes: Past, Present, and Future
Laakso, M., & Silva, L. F. (2022) · Nutrients · doi:10.3390/nu14153201 · Cited by 108
Human Digital Twin for Personalized Elderly Type 2 Diabetes Management
Thamotharan, P., Srinivasan, S., Kesavadev, J., Krishnan, G., Mohan, V., Seshadhri, S., Bekiroglu, K., & Toffanin, C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062094 · Cited by 106
Metadata
- Authors
- Williams, D. M., Jones, H., & Stephens, J. W.
- Affiliations
- Swansea Bay University Health Board (GB)
- Corresponding author
- Williams, David M
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2022-02
- Volume
- Volume 15
- Pages
- 281-295
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC8824792
- OpenAlex
- W4210447482
- Cited by
- 121
- References
- 107
- Citations by year
- 2026: 19 · 2025: 41 · 2024: 31 · 2023: 21 · 2022: 9
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 2 diabetes, personalized medicine, glycemic control, diabetes pharmacotherapy, diabetes phenotypes, genetic biomarkers, comorbidities, hypoglycemia, medication adherence, patient satisfaction, quality of life, diabetes distress, weight management, treatment goals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.